P1.074. SNORD33-Driven 18S rRNA 2′-O-Methylation Licenses TNFSF9–4-1BB Signaling and Sensitizes ESCC to PD-1 Blockade
Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Neoadjuvant PD-1/PD-L1 based immunotherapy improve outcomes for resectable esophageal squamous cell carcinoma (ESCC), but patient outcome are heterogeneous and robust pretreatment blood biomarkers are lacking. We performed an unbiased plasma sno...